EP2552449A2 — Improved methods and compositions for safe and effective treatment of erythema
Assigned to Galderma Research and Development SNC · Expires 2013-02-06 · 13y expired
What this patent protects
Improved methods and compositions for safe and effective treatment of erythemaora symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight ofbrim…
USPTO Abstract
Improved methods and compositions for safe and effective treatment of erythemaora symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight ofbrimonidine and a pharmaceutically acceptable carrier.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.